SEC Form 4 · accession 0000310158-26-000214
Merck & Co., Inc. · MRK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Michael Williams
Officer — EVP,Chief Info&Digital Officer
Period of report
Aug 5, 2026
Accepted (ET)
Aug 7, 2026 · 4:19 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000310158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 5, 2026 | M | 4,600 | $77.62 | A | 36,316 | D | |
| Common StockF1 | Aug 5, 2026 | S | 4,600 | $128.7707 | D | 31,716 | D | |
| Common Stock | Aug 5, 2026 | M | 13,542 | $75.36 | A | 45,258 | D | |
| Common StockF1 | Aug 5, 2026 | S | 13,542 | $128.7707 | D | 31,716 | D | |
| Common Stock | Aug 5, 2026 | M | 34,705 | $73.73 | A | 66,421 | D | |
| Common StockF1 | Aug 5, 2026 | S | 34,705 | $128.7707 | D | 31,716 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $77.62 | Aug 5, 2026 | M | 4,600 | D | May 3, 2020 | May 2, 2029 | Common Stock | 4,600 | 0 | D |
| Stock Option (Right to Buy)F3,F4 | $75.36 | Aug 5, 2026 | M | 13,542 | D | May 1, 2021 | Apr 30, 2030 | Common Stock | 13,542 | 0 | D |
| Stock Option (Right to Buy)F3,F5 | $73.73 | Aug 5, 2026 | M | 34,705 | D | May 4, 2022 | May 3, 2031 | Common Stock | 34,705 | 0 | D |
Explanation of responses
- F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- F2The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022.
- F3Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
- F4The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
- F5The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024.